(S)-N-(piperidin-3-ylmethyl)-7-(1H-pyrazol-4-yl)pyrido[4,3-b]pyrazin-5-amine

ID: ALA4570285

PubChem CID: 66556535

Max Phase: Preclinical

Molecular Formula: C16H19N7

Molecular Weight: 309.38

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  c1cnc2c(NC[C@H]3CCCNC3)nc(-c3cn[nH]c3)cc2n1

Standard InChI:  InChI=1S/C16H19N7/c1-2-11(7-17-3-1)8-20-16-15-14(18-4-5-19-15)6-13(23-16)12-9-21-22-10-12/h4-6,9-11,17H,1-3,7-8H2,(H,20,23)(H,21,22)/t11-/m0/s1

Standard InChI Key:  MTOXIGVDKCMGPO-NSHDSACASA-N

Molfile:  

 
     RDKit          2D

 23 26  0  0  0  0  0  0  0  0999 V2000
   11.5548  -10.4707    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5537  -11.2903    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.2617  -11.6992    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.2599  -10.0619    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.9686  -10.4671    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.9693  -11.2862    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6778  -11.6932    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.3861  -11.2824    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.3814  -10.4603    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.6723  -10.0569    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6679   -9.2397    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.3735   -8.8274    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.0833   -9.2322    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.0830  -10.0463    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.7888  -10.4510    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4968  -10.0422    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4944   -9.2240    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.7841   -8.8148    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.1000  -11.6899    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.1886  -12.5023    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.9886  -12.6691    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.3945  -11.9597    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.8453  -11.3547    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  6  2  0
  5  4  2  0
  4  1  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10  5  1  0
 10 11  1  0
 11 12  1  0
 13 12  1  6
 13 14  1  0
 13 18  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 19 20  2  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
 23 19  1  0
  8 19  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4570285

   N-[[(3S)-piperidin-3-yl]methyl]-7-(1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-5-amine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 309.38

Molecular Weight (Monoisotopic): 309.1702

AlogP: 1.83

#Rotatable Bonds: 4

Polar Surface Area: 91.41

Molecular Species: BASE

HBA: 6

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 11.95

CX Basic pKa: 10.17

CX LogP: 0.52

CX LogD: -2.01

Aromatic Rings: 3

Heavy Atoms: 23

QED Weighted: 0.68

Np Likeness Score: -1.02

References

1. Garton NS, Barker MD, Davis RP, Douault C, Hooper-Greenhill E, Jones E, Lewis HD, Liddle J, Lugo D, McCleary S, Preston AGS, Ramirez-Molina C, Neu M, Shipley TJ, Somers DO, Watson RJ, Wilson DM..  (2016)  Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors.,  26  (19): [PMID:27578246] [10.1016/j.bmcl.2016.08.070]

Source

Source(1):

• Scientific Literature